

# The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Louis Messina
Enrollment	10 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- PAD as demonstrated by an ABI  $\leq 0.9$  in one leg or TBI less than  $\leq 0.7$  in patients with an ABI  $\geq 1.3$  (non compressible vessels)
- Rutherford Classification II, III
- Age  $\geq 18$  years old
- Willingness to discontinue phosphodiesterase (PDE) 5 inhibitors such as Viagra, Cialis, Levitra, Revatio
- Willingness to discontinue phosphodiesterase (PDE) 3inhibitors cilostazol, milrinone or Vesnarinone
- ... and 3 more (see full listing online)

### Exclusion (19)

- Hypotension defined as a systolic blood pressure less than 100mmhg systolic at screening or baseline visit
- Critical Leg Ischemia (Rutherford Classification IV, V, VI)
- Surgical intervention to alleviate symptoms of claudication in the study leg within the past 6 months or any endovascular interventions within 3 months or who is scheduled to undergo surgical revascularization in the next 6 month
- Walking limited by reasons other than claudication (e.g. arthritis, lung disease, severe neuropathy, lower extremity amputation except single digits)
- Serum creatinine  $\geq 1.5$ mg/dl or Hepatic enzymes  $\geq 2X$  the upper limit of normal
- ... and 14 more (see full listing online)

## Locations (1 total)

---

UMASS Memorial Healthcare - University Campus, Worcester, Massachusetts, United States